[Pubmed] Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
Posté : 23 juin 2023 12:00
Neurol Ther. 2023 Jun 23. doi: 10.1007/s40120-023-00514-4. Online ahead of print.
ABSTRACT
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).
PMID:37351816 | DOI:10.1007/s40120-023-00514-4
Source: https://pubmed.ncbi.nlm.nih.gov/3735181 ... t6+86293ac